We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
178 result(s) found, displaying 61 to 70
-
Designation or determinationPriority review
-
Section 14, TGO91 consentProduct(s) approved for Supply with noncompliant labelling.
-
Section 14, TGO91 consentProduct(s) approved for Supply with noncompliant labelling.
-
Prescription medicine registrationActive ingredients: nivolumab.
-
Prescription medicine registrationActive ingredients: ipilimumab.
-
Prescription medicine registrationActive ingredients: dasatinib.
-
Australian public assessment report (AusPar)Australian Public Assessment Report for Nivolumab
-
Australian public assessment report (AusPar)Australian Public Assessment Report for Nivolumab
-
Australian public assessment report (AusPar)Australian Public Assessment for Dasatinib
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for EMPLICITI elotuzumab 300mg lyophilized powder for IV infusion vial.